Efficacy and safety of chloroquine for treatment in patients with uncomplicated Plasmodium vivax infections in endemic countries

Transactions of the Royal Society of Tropical Medicine and Hygiene

Volumn 104, Issue 11, 2010, Pages 695-705

  Naing, Cho ^a   Aung, Kyan ^a   Win, Daw Khin ^a   Wah, Mak Joon ^a  

^a INTERNATIONAL MEDICAL UNIVERSITY   (Malaysia)

Author keywords

Chloroquine; Meta analysis; Plasmodium vivax; Randomized controlled trial; Treatment

Indexed keywords

ARTEMETHER; ARTEMETHER PLUS ARTESUNATE; ARTEMISININ; AZITHROMYCIN; CHLOROQUINE; CHLORPROGUANIL PLUS DAPSONE; DAPSONE; FANSIDAR; HALOFANTRINE; MEFLOQUINE; PRIMAQUINE; PROGUANIL; QUININE; TAFENOQUINE; UNCLASSIFIED DRUG;

ABDOMINAL PAIN; CLINICAL TRIAL; COMBINATION CHEMOTHERAPY; DRUG EFFICACY; DRUG SAFETY; HEADACHE; HUMAN; MONOTHERAPY; NAUSEA; PLASMODIUM VIVAX MALARIA; REVIEW; SINGLE DRUG DOSE; VOMITING;

ANTIMALARIALS; CHLOROQUINE; ENDEMIC DISEASES; HUMANS; MALARIA, VIVAX; PLASMODIUM VIVAX; TREATMENT OUTCOME;

PLASMODIUM VIVAX;

EID: 77957994982     PISSN: 00359203     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.trstmh.2010.08.009     Document Type: Review

References (54)

1. Sina B. Focus on Plasmodium Vivax. Trends Parasitol 2002, 18:287-289.
2. WHO. Monitoring Antimalarial Drug Resistance (Report of a WHO Consultation 3-5 December 2001). Geneva: World Health Organization; 2002. (WHO/CDS/CSR/EPH/2002.17).
3. Price R.N., Tjitra M., Guerra C.A., Yeung S., White N.J., Anstey N.M. Vivax malaria: neglected and not benign. Am J Trop Med Hyg 2007, 77:79-87.
4. Nosten F., Mcgready R., Simpson J.A. Effects of Plasmodium vivax malaria in pregnancy. Lancet 1999, 354:546-549.
5. Myat-Phone-Kyaw, Myint-Oo Myint-Lwin. Emergence of chloroquine-resistant Plasmodium vivax in Myanmar (Burma). Trans R Soc Trop Med Hyg 1993, 87:687.
6. Kurcer M.A., Simsek Z., Zeyrek F.Y., Atay S., Çelik H., Kat I., et al. Efficacy of chloroquine in the treatment of Plasmodium vivax malaria in Turkey. Ann Trop Med Parasitol 2004, 98:447-451.
7. Teka H, Petros B, Yamuah L, Tesfaye G, Elhassan I, Muchohi S et al., Chloroquine-resistant Plasmodium vivax malaria in Debre Zeit, Ethiopia. Malar J 2008; 29;7:220.
8. Lee K.S., Kim T.H., Kim E.S., Lim H.S., Yeom J.S., Jun G., et al. Short report: chloroquine-resistant Plasmodium vivax in the Republic of Korea. Am J Trop Med Hyg 2009, 80:215-217.
9. Barnadas C., Ratsimbasoa A., Tichit M., Bouchier C., Jahevitra M., Picot S., et al. Plasmodium vivax resistance to chloroquine in Madagascar: clinical efficacy and polymorphisms in pvmdr1 and pvcrt-o genes. Antimicrob Agents Chemother 2008, 52:4233-4240.
10. Schwobel B., Jordan S., Vanisaveth V., Phetsouvanh R., Christophel E.M., Phompida S., et al. Therapeutic efficacy of chloroqione plus sulphadoxine/pyrimethamine compared with monotherapy with either in uncomplicated P falciparum malaria in Laos. Trop Med Int Health 2003, 8:19-24.
11. Vijaykadga S., Rojanawatsirivej C., Congpoung K., Wilairatana P., Satimai W., Uaekowitchai C., et al. Assessment of therapeutic efficacy of Chloroquine for vivax malaria in Thailand. Southeast Asian J Trop Med Public Health 2004, 35:566-569.
12. Srivastava H.C., Yadav R.S., Joshi H., Valecha N., Mallick P.K., Prajapati S.K., et al. Therapeutic responses of Plasmodium vivax and P. falciparum to chloroquine,in an area of western India where P. vivax predominates. Ann Trop Med Parasitol 2008, 102:471-480.
13. Pullman T.N., Craige B., Alving A.S., Whorton C.M., Jones R., Eichelberger L. Comparison of chloroquine, quinacrine (atabrine) and quinine in the treatment of acute attacks of sporozoite-induced vivax malaria, Chesson strain. J Clin Invest. 1948, 27(3 Pt1):46-50.
14. World Health Organization. Report of the third country meeting of national malaria control managers, Lahore, Pakistan, 12-15 May 2003. WHO-EMRO, Cairo. 2004; (WHO/CDS/RBM/2002.39).
15. White N.J., Pongtavornpinyo W., Maude R.J., Saralamba S., Aguas R., Stepniewska K., et al. Hyperparasitaemia and low dosing are an important source of anti-malarial drug resistance. Malar J 2009, 8:253. 10.1186/1475-2875-8-253.
16. Petitti DB., Meta-analysis. In: Meta-analysis, decision tree analysis, and cost-effectiveness analysis. 2nd ed. (Monographs in Epidemiology and biostatistics volume 31) Oxford University Press, 2000; 2-3.
17. Kalanda G.C., Hill J., Francine H., Verhoeff F.H., Brabin B.J. Comparative efficacy of chloroquine and sulphadoxine-pyrimethamine in pregnant women and children: a meta-analysis. Trop Med Int Health 2006, 11:569-577.
18. PrayGod G, Frey A de, Eisenhut M. Artemesinin derivatives versus quinine in treating severe malaria in children: a systematic review. Malar J 2008; 7:210. doi:10.1186/1475-2875-7-210.
19. Galappathay GNL, Omarai AAA, Tharyan P. Primaquine for preventing relapses in people with Plasmodium vivax malaria. Cochrane Database of Systematic Reviews 2009, Issue 1. Art. No. CD004389. (). doi:10.1002/14651858.CD004389.pub2.
20. Griffith K.S., Lewis L.S., Mali S., Parise M.E. Treatment of malaria in the United States: a systematic review. JAMA 2007, 297:2264-2277.
21. Cochrane Handbook for Systematic Reviews of Interventions July 2009, Wiley-Blackwell, West Sussex, England. J.P.T. Higgins, S. Green (Eds.).
22. The Cochrane Collaboration. Reviewer manager software (RevMan) version 5.0. Oxford, UK: The Cochrane Collaboration; 2008.
23. Dunne W.M., Singh N. A double blind, randomised study of Azithromycin compared to chloroquine for the treatment of Plasmodium vivax malaria. Am J Trop Med Hyg 2005, 73:1108-1111.
24. Gogtay N.J., Desai S., Kamtekar K.D., Kadam V.S., Dalvi S.S., Kshirsagar N.A. Efficacy of 5- and 14- day primaquine regimen in the prevention of relapses in Plasmodium vivax infections. Ann Trop Med Parasitol 1999, 93:809-812.
25. Kolaczinski K., Durrani N., Rahim S., Rowland M. Sulphadoxine-pyrimethamine plus artesunate compared with chloroquine for the treatment of vivax malaria in areas co-endemic for Plasmodium falciparum and P vivax: a randomised non-inferiority trial in eastern Afghanistan. Trans R Soc Trop Med 2007, 101:1081-1087.
26. Krudsood S., Tangpukdee N., Muangnoicharoen S., Thanchartwet V., Luplertilop N., Srivilairit S., et al. Clinical efficacy of chloroquine versus artemether-lumefantrine for Plasmodium vivax treatment in Thailand. Korean J Parasitol 2007, 45:111-114.
27. Leslie T., Rab M.A., Ahmadzai H., Durani N., Fayaz M., Kolaczinski J., et al. Compliance with 14-day primaquine therapy for radical cure of vivax malaria- a randomised placebo-controlled trial comparing unsupervised with supervised treatment. Trans R Soc Trop Med Hyg 2004, 98:168-173.
28. Leslie T., Mayan M.I., Hasan M.A., Safi M.H., Klinkenberg E., Whitty C.J.M., et al. Sulfadoxine-pyrimethamine, chlorproguanil-dapsone, or chloroquine for the treatment of Plasmodium vivax malaria in Afghanistan and Pakistan: a randomized controlled trial. JAMA 2007, 297:2201-2220.
29. Leslie T, Mayan MI, Mohammed N, Erasmus P, Kolaczinski J, Whitty CJM, et al. A randomized controlled trial of 8 weeks, once weekly primaquine regimen to prevent relapse of Plasmodium vivax in Northwest Frontier Province, Pakistan. PLoS ONE 2008; 3:e2861. doi:10.1371/journal.pone.0002861.
30. Looareesuwan S., Wilairatana P., Krudsood S., Treeprasertsuk S., Singhasivanon P., Bussaratid V., et al. Chloroquine sensitivity of Plasmodium vivax in Thailand. Ann Trop Med Parasitol 1999, 93:225-230.
31. Phan GT, J de Vries P, Tran BQ, Hung Q, Le HQ, Nguyen NV et al., Artemisinin or chloroquine for blood stage Plasmodium vivax malaria in Vietnam. Trop Med Int Health 2002; 7:858-64.
32. Pukrittayakamee S., Chantra A., Simpson J.A., Vanijanonta S., Clemens R., Looareesuwan S., et al. Therapeutic responses to different antimalarial drugs in vivax malaria. Antimicrob Agents Chemother 2000, 44:1680-1685.
33. Rajgor D.D., Gogtay N.J., Kadam V.S., Kamtekar K.D., Dalvi S.S., Chogle A.R., et al. Efficacy of a 14-day primaquine regimen in preventing relapses in patients with Plasmodium vivax malaria in Mumbai, India. Trans R Soc Trop Med Hyg 2003, 438-440.
34. Rowland M., Durrani N. Randomized controlled trials of 5- and 14-days primaquine therapy against relapses of vivax malaria in an Afghan refugee settlement in Pakistan. Trans R Soc Trop Med Hyg 1999, 93:641-643.
35. Walsh D.S., Wilairatana P., Tang D.B., Heppner D.G., Brewer T.G., Krudsood S., et al. Randomized trial of 3-dose regimens of tafenoquine (WR238605) versus low-dose primaquine for preventing Plasmodium vivax malaria relapse. Clin Infect Dis 2004, 39:1009-1103.
36. Yadav R.S., Ghosh S.K. Radical curative efficacy of 5 day regimen of primaquine for treatment Plasmodium vivax malaria in India. J Parasitol 2002, 88:1042-1044.
37. Yeshiwondim A.K., Tekle A.H., Dengela D.O., Yohannes A.M., Teklehaimanot A. Therapeutic efficacy of chloroquine and chloroquine plus primaquine for the treatment of Plasmodium vivax in Ethiopia. Acta Trop 2009, 10.1016/j.actatropica.2009.10.001.
38. Villalobos-Salcedo JM, Tada. In-vivo sensitivity. Annal Trop Med Parasitol 2000; 94:749-58.
39. Marfurt J., Müeller I., Sie A., Maku P., Goroti M., Reeder J.C., et al. Low efficacy of amodiaquine or chloroquine plus sulfadoxine-pyrimethamine against Plasmodium falciparum and P. vivax malaria in Papua New Guinea. Am J Trop Med Hyg 2007, 77:947-954.
40. Fryauff D.J., Tuti S., Mardi A., Masbar S., Patipelohi R., Leksana B., et al. Chloroquine-resistant Plasmodium vivax in transmigration settlements of West Kalimantan. Indonesia Am J Trop Med Hyg 1998, 59:513-518.
41. Guthmann J-P, Pittet A, Lesage A, Imwong M, Lindegardh N, Myo Min Lwin et al., Plasmodium vivax resistance to chloroquine in Dawei, Southern Myanmar. Trop Med Int Health 2008; 13:91-8.
42. Marlar-Than, Myat-Phone-Kyaw, Aye-Yu-Soe, Khaing-Khaing-Gyi, Ma-Sabai, Myint-Oo. Development of resistance to chloroquine by Plasmodium vivax in Myanmar. Trans R Soc Trop Med Hyg 1995; 89:307-8.
43. Ketema T., Bacha K., Birhanu T., Petros B. Chloroquine-resistant Plasmodium vivax malaria in Serbo town, Jimma zone, south-west Ethiopia. Malar J 2009, 30. 10.1186/1475-2875-8-177.
44. Sutanto I., Suprijanto S., Nurhayati, Manoempil P., Baird J.K. Resistance to chloroquine by Plasmodium vivax at Alor in the Lesser Sundas Archipelago in eastern Indonesia. Am J Trop Med Hyg. 2009, 81:338-342.
45. Pukrittayakamee S., Imwong M., Looareesuwan S., White N. Therapeutic responses to antimalarial and antibacterial drugs in vivax malaria. Acta Trop 2004, 89:351-356.
46. Ranque S., Badiaga S., Delmont J., Brouqui P. Triangular test applied to the clinical trial of azithromycin against relapses in Plasmodium vivax infections. Malar J 2002, 1:13.
47. Tjitra E., Baker J., Suprianto S., Cheng Q., Anstey N.M. Therapeutic efficacies of artesunate-sulfadoxine-pyrimethamine and chloroquine-sulfadoxine-pyrimethamine in vivax malaria pilot studies: relationship to Plasmodium vivax dhfr mutations. Antimicrob Agents Chemother 2002, 46:3947-3953.
48. Baird J.K., Leksana B., Masbar S., Fryauff D.J., Sutanihardja M.A., Suradi, et al. Diagnosis of resistance to chloroquine by Plasmodium vivax: timing of recurrence and whole blood chloroquine levels. Am J Trop Med Hyg 1997, 56:621-626.
49. Baird J.K. Resistance to therapies for infection by Plasmodium vivax. Clin Microbiol Rev. 2009, 22:508-534.
50. WHO. Practical Chemotherapy of Malaria. Geneva: World Health Organization, Technical Report Series, no 805. 1990.
51. WHO. Guidelines for the Treatment of Malaria. Geneva: World Health Organization 2005; (WHO/HTM/MAL/2006.110).
52. WHO. World Malaria Report 2008. Geneva: World Health Organization; 2008. (). [accessed 10 April 2010]. http://whqlibdoc.who.int/publications/2008/9789241563697_eng.pdf.
53. Myint H.Y., Tipmanee P., Nosten F., Day N.P.J., Pukrittayakamee S., Looareesuwan S., et al. A systematic overview of published antimalarial drug trials. Trans R Soc Trop Med Hyg 2004, 98:73-81.
54. Stepniewska S., White N.J. Some considerations in the design and interpretation of antimalarial drug trials in uncomplicated falciparum malaria. Malar J 2006, 5:127. 10.1186/1475-2875-5-127.